Antipodean Advisors’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-321,000
| Closed | -$27.3M | – | 9 |
|
|
2019
Q4 | $27.3M | Hold |
321,000
| – | – | 15.6% | 3 |
|
|
2019
Q3 | $16.1M | Buy |
321,000
+64,000
| +25% | +$2.55M | 13.39% | 5 |
|
|
2019
Q2 | $9.37M | Buy |
257,000
+87,000
| +51% | +$2.84M | 11.4% | 4 |
|
|
2019
Q1 | $4.75M | Buy |
170,000
+41,000
| +32% | +$966K | 3.38% | 7 |
|
|
2018
Q4 | $2.47M | Buy |
129,000
+47,000
| +57% | +$1.09M | 4.68% | 6 |
|
|
2018
Q3 | $2.45M | Sell |
82,000
-83,500
| -50% | -$3.15M | 3.04% | 8 |
|
|
2018
Q2 | $6.07M | Sell |
165,500
-72,000
| -30% | -$2.34M | 7.66% | 6 |
|
|
2018
Q1 | $7.82M | Buy |
237,500
+139,500
| +142% | +$4.36M | 8.65% | 5 |
|
|
2017
Q4 | $2.68M | Sell |
98,000
-78,000
| -44% | -$2.4M | 2.18% | 11 |
|
|
2017
Q3 | $6.52M | Sell |
176,000
-398,434
| -69% | -$14.7M | 5.5% | 8 |
|
|
2017
Q2 | $21.8M | Sell |
574,434
-256,000
| -31% | -$11.4M | 12.28% | 1 |
|
|
2017
Q1 | $40.6M | Buy |
830,434
+598,000
| +257% | +$27.3M | 19.82% | 1 |
|
|
2016
Q4 | $7.89M | Sell |
232,434
-50,000
| -18% | -$1.77M | 3.16% | 11 |
|
|
2016
Q3 | $10.7M | Sell |
282,434
-184,789
| -40% | -$6.96M | 5.27% | 10 |
|
|
2016
Q2 | $15.7M | Sell |
467,223
-255,000
| -35% | -$8.99M | 9.5% | 2 |
|
|
2016
Q1 | $22.9M | Sell |
722,223
-1,023,077
| -59% | -$33.4M | 10.4% | 2 |
|
|
2015
Q4 | $65.2M | Sell |
1,745,300
-692,700
| -28% | -$26.2M | 9.51% | 4 |
|
|
2015
Q3 | $92.5M | Buy |
+2,438,000
| New | +$85.6M | 10.54% | 4 |
|
Other funds holding MDCO
Antipodean Advisors's MDCO Position: Q1 2020 in Review
Antipodean Advisors sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 321,000 shares — an estimated $27.3M sold.
Antipodean Advisors first reported a position in MDCO in Q3 2015 and held it in 18 quarters. The position peaked at $92.5M in Q3 2015. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Antipodean Advisors reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Antipodean Advisors sold 321,000 Medicines Co shares in Q1 2020, an estimated $27.3M.
- Antipodean Advisors first reported a position in Medicines Co in Q3 2015 and held it in 18 quarters.
- Antipodean Advisors's Medicines Co position peaked at $92.5M in Q3 2015.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Antipodean Advisors's 13F filing for Q1 2020, filed 15 May 2020.